BCEL(Delisted)
Atreca·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCEL
Atreca, Inc.
A clinical-stage biotechnology company focused on developing novel therapeutics based on interrogation of the active human immune response
835 Industrial Road, Suite 400, San Carlos, CA 94070
--
Atreca, Inc., was incorporated in Delaware on June 11, 2010. The Company is a biopharmaceutical company that utilizes its differentiated platform to discover and develop novel antibody immunotherapeutic agents to treat multiple solid tumor types. The company's lead product candidate, ATRC-101, is a preclinically developed monoclonal antibody with a novel mechanism of action and a target derived from antibodies identified using its discovery platform. Since its establishment, the company has mainly engaged in research and development, raising funds, building management teams and building intellectual property portfolios.
Company Financials
EPS
BCEL has released its 2023 Q3 earnings. EPS was reported at -0.92, versus the expected -0.38, missing expectations. The chart below visualizes how BCEL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
